v3.26.1
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Treasury Stock, Common
Balance at beginning of period at Oct. 31, 2024 $ 1,010,746 $ 513 $ 701,008 $ 430,405 $ (46,428) $ (74,752)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (14,885)     (14,885)    
Foreign currency translation adjustment (15,951)       (15,951)  
Common dividends ($0.08 per share) (3,812)     (3,812)    
Purchase of treasury stock (3,698)         (3,698)
Stock-based compensation activity:            
Expense related to stock-based compensation 902   902      
Stock options exercised 214   41     173
Restricted stock awards granted     (1,894)     1,894
Performance restricted stock units vested     (1,300)     1,300
Other (1,400) (1) (1,399)      
Balance at end of period at Jan. 31, 2025 972,116 512 697,358 411,708 (62,379) (75,083)
Balance at beginning of period at Oct. 31, 2024 1,010,746 513 701,008 430,405 (46,428) (74,752)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 5,630          
Balance at end of period at Apr. 30, 2025 1,001,663 512 698,238 428,483 (27,034) (98,536)
Balance at beginning of period at Jan. 31, 2025 972,116 512 697,358 411,708 (62,379) (75,083)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 20,515     20,515    
Foreign currency translation adjustment 35,345       35,345  
Common dividends ($0.08 per share) (3,740)     (3,740)    
Purchase of treasury stock (23,496)         (23,496)
Stock-based compensation activity:            
Expense related to stock-based compensation 923   923      
Restricted stock awards granted     (43)     43
Balance at end of period at Apr. 30, 2025 1,001,663 512 698,238 428,483 (27,034) (98,536)
Balance at beginning of period at Oct. 31, 2025 726,179 512 700,029 164,710 (35,439) (103,633)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (4,071)     (4,071)    
Foreign currency translation adjustment 11,110       11,110  
Common dividends ($0.08 per share) (3,676)     (3,676)    
Stock-based compensation activity:            
Expense related to stock-based compensation 1,166   1,166      
Restricted stock awards granted     (5,415)     5,415
Other (354)   (354)      
Balance at end of period at Jan. 31, 2026 730,354 512 695,426 156,963 (24,329) (98,218)
Balance at beginning of period at Oct. 31, 2025 726,179 512 700,029 164,710 (35,439) (103,633)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss (721)          
Balance at end of period at Apr. 30, 2026 727,358 512 696,391 156,641 (27,897) (98,289)
Balance at beginning of period at Jan. 31, 2026 730,354 512 695,426 156,963 (24,329) (98,218)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss 3,350     3,350    
Foreign currency translation adjustment (3,568)       (3,568)  
Common dividends ($0.08 per share) (3,672)     (3,672)    
Stock-based compensation activity:            
Expense related to stock-based compensation 1,236   1,236      
Restricted stock awards granted     (211)     211
Other (342)   (60)     (282)
Balance at end of period at Apr. 30, 2026 $ 727,358 $ 512 $ 696,391 $ 156,641 $ (27,897) $ (98,289)